Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Daraxonrasib Combo Shows 90% Disease Control in Advanced Pancreatic Cancer Trial

Daraxonrasib Combo Shows 90% Disease Control in Advanced Pancreatic Cancer Trial

November 20, 2026 Health Desk Health

A new clinical trial for the drug daraxonrasib has demonstrated significant tumor response rates in patients with advanced pancreatic cancer, offering a potential shift in standard treatment protocols.

According to data reported by alarabiya.net, the drug, when paired with standard chemotherapy, halted tumor progression in 90% of the 61 participants involved in the early-stage study.

Key Clinical Takeaways:

  • Daraxonrasib, when combined with chemotherapy, successfully stabilized or reduced tumor growth in 90% of clinical trial participants.
  • The treatment specifically targets RAS genetic mutations, which are prevalent in the majority of pancreatic cancer cases and often associated with other malignancies like lung and ovarian cancer.
  • While the initial results are promising, researchers emphasize that further long-term studies are required to confirm if these radiological responses translate into sustained survival benefits.

Pancreatic cancer remains one of the most clinically challenging malignancies, primarily due to delayed detection and limited therapeutic options. The experimental drug daraxonrasib acts by disrupting the molecular signaling pathways that RAS mutations utilize to drive cellular proliferation.

As noted by alarabiya.net, more than 60% of the trial participants experienced tumor shrinkage or complete clinical regression. In approximately 8% of cases, the tumors were no longer visible on computed tomography (CT) scans.

During the study, which monitored participants for an average of 18 months, some patients maintained disease control without evidence of tumor recurrence.

The updated results from the Phase I and II clinical trials were presented at the EORTC-NCI-AACR symposium in Barcelona. Investing.com reported that the study utilized a 200 mg dose of the drug in combination with gemcitabine and nab-paclitaxel. The data indicated a 90.2% disease control rate, with a median duration of response lasting 11.1 months.

Metric Trial Result
Study Population 61 Patients
Disease Control Rate 90.2%
Median Response Duration 11.1 Months
Average Follow-up 18.3 Months

Despite the positive radiological findings, clinicians caution against premature conclusions regarding a definitive cure.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: PECATI Trial: Lenvatinib Plus Pembrolizumab Shows 40.2-Month Median OS in Pretreated Thymic Tumors · Experimental GLS1 Inhibitor IACS-6274 Shrinks Tumors in Advanced Treatment-Resistant Ovarian Cancer Phase I Trial

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • Google Faces Criminal Probe in Finland Over Alleged Data Center Environmental Infractions
  • Disabling Cellular Recycling Gene Boosts Hard-to-Make Drug Protein Yields
  • Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)
  • Study Finds Sensory Reweighting Drives Postural Control After Amputation (time.news)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service